
Develop-Players is a company that develops digital solutions to support children, adolescents, and adults with neurodivergent profiles such as ADHD and specific learning disorders (DSA). Their offerings combine technology, scientific research, and human support to provide personalized clinical pathways from screening to cognitive enhancement. Key products include SAM, a scientifically validated interactive digital screening test for ADHD and DSA, and Eye-Riders, a serious game designed to improve attention and executive functions in children and adolescents. The company emphasizes accessibility, engagement through gamification, and continuous human support, positioning itself as an innovative, reliable, and validated ecosystem for families and clinicians. Based in Italy, Develop-Players integrates clinical expertise with digital innovation to address neurodiversity needs effectively.

Develop-Players is a company that develops digital solutions to support children, adolescents, and adults with neurodivergent profiles such as ADHD and specific learning disorders (DSA). Their offerings combine technology, scientific research, and human support to provide personalized clinical pathways from screening to cognitive enhancement. Key products include SAM, a scientifically validated interactive digital screening test for ADHD and DSA, and Eye-Riders, a serious game designed to improve attention and executive functions in children and adolescents. The company emphasizes accessibility, engagement through gamification, and continuous human support, positioning itself as an innovative, reliable, and validated ecosystem for families and clinicians. Based in Italy, Develop-Players integrates clinical expertise with digital innovation to address neurodiversity needs effectively.
Headquarters: Cesena, Emilia-Romagna, Italy
Focus: Digital screening and cognitive training for neurodevelopmental conditions (ADHD, DSA)
Flagship products: SAM (digital screening), Eye-Riders (serious game for attention/executive functions)
Funding: Pre-Seed round closed Dec 27, 2023; investors include Opes Italia, Privilège Ventures, 20Fund
Assessment and cognitive rehabilitation/support for neurodevelopmental conditions (DSA, ADHD) in children and adolescents.
2021
Health tech / Digital therapeutics / Edtech
Round included participation from Privilège Ventures and 20Fund
“Opes Italia, Privilège Ventures, 20Fund participated in Pre-Seed”